These include two different variants in POLE in two different tumors; two different variants in CHEK2 in two different tumors; one variant in BRIP1 and PTCH1 both in a single tumor; and additional rare variants, one per tumor (e.g., TP53, MET, EGFR, among others, Supplementary Data 6). This evidence concerns the gene BRIP1 and neoplasm.